INSY

Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News

By William White, InvestorPlace Writer
Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher on approval for the company's First Day motions,

Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News

By William White, InvestorPlace Writer
The Insys Therapeutics bankruptcy news coming out on Monday about it filing for Chapter 11 has INSY stock tanking hard today.

Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use

By James Brumley, InvestorPlace Feature Writer
It's not a great reason in and of itself to buy CGC stock , but Canopy Growth does have an overlooked presence in the medical cannabis arena.

You Can Get Buy Signals From Short Selling

By Mark Putrino, CMT
A high short interest in a stock could be a buy signal. That is becaise the short sellers will eventually need to buy it back.

7 Pharmaceutical Stocks That Just Raised Prices This Year

By Bret Kenwell, InvestorPlace Contributor
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?

7 U.S. Marijuana Stocks to Buy for the Midterm Elections

By Josh Enomoto, InvestorPlace Contributor
Marijuana stocks have endured some of the worst from the October fallout, but a few American names have substantial potential.

9 Marijuana Stocks to Play the Pot Craze

By James Brumley, InvestorPlace Feature Writer
Marijuana stocks like Cronos, Cannabis Sativa and Canopy Growth are just a handful of the names worth a closer look here.

2 Marijuana Biotechs to Watch

By InvestorPlace Research Staff
Things may be looking up for marijuana stocks, as a cannabidiol (CBD)-based drug was rescheduled to Schedule 5. These 2 should profit next.

4 Drug and Biotech Stocks Awaiting FDA Decisions in July

By
In the first six months of the year, the FDA grants approval to 17 new treatments. Compare Brokers....

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

3 Marijuana Stocks to Buy on a Federal Crackdown

By Wayne Duggan, InvestorPlace Contributor
For marijuana stocks like GWPH, ZYNE and INSY, a federal crackdown on marijuana legalization laws is no big deal.

3 Marijuana Stocks That Will Burn Out In 2017

By Wayne Duggan, InvestorPlace Contributor
While 2016 was a big year for marijuana stocks, 2017 could give the industry fits. Watch out for these three popular marijuana companies.

3 Trump Stocks That Are All Trumped Out

By Wayne Duggan, InvestorPlace Contributor
These Trump stocks have gained so much that traders should take profits now: DryShips (DRYS), SAExploration (SAEX) and Insys (INSY).

52 Biotechnology Stocks to Sell Now

By Portfolio Grader
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Pharma Stocks That Could Be Gutted If Marijuana Wins

By Wayne Duggan, InvestorPlace Contributor
If marijuana initiatives perform well on Election Day, opioid pharma stocks such as MYL, DEPO and INSY could be the big losers.

30 Biotechnology Stocks to Sell Now

By Portfolio Grader
The ratings of 30 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Marijuana Stocks Could Get Lit This November

By Wayne Duggan, InvestorPlace Contributor
While most investors are focused on who becomes the next president, marijuana stocks are watching legalization votes in nine key states.

32 Biotechnology Stocks to Sell Now

By Portfolio Grader
The ratings of 32 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

41 Biotechnology Stocks to Sell Now

By Portfolio Grader
The overall ratings of 41 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Load More